Medical Crossfire®: Sequencing of Disease Modifying Therapies – Optimizing Outcomes in Patients with Multiple Sclerosis

Acknowledgement of Commercial Support:

This activity is supported by educational grant from Biogen.

The educational activity is jointly provided by:

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review key clinical trial data for current and emerging therapies for the treatment of MS
• Implement strategies to select optimal evidence-based treatments for patients in the early stages of MS
• Formulate individualized treatment plans for patients with MS
• Discuss approaches to shared decision-making to optimize patient adherence to the selected treatment plan

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 
 

Chair

Patricia K. Coyle, MD
Professor and Vice Chair of Clinical Affairs
Director MS Comprehensive Care Center
Department of Neurology
Stony Brook University Medical Center
Stony Brook, NY
 

Disclosures: Grant/Research Support: Actelion, Alkermes, Celgene, CorEvitas, Genentech/Roche, Genzyme/Sanofi, Janssen Pharmaceutical Companies of Johnson & Johnson, MedDay, National Institute of Neurological Disorders and Stroke, Novartis. Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, Genzyme/Sanofi, GlaxoSmithKline, Horizon Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson, Mylan, Novartis, Viela Bio. Speaker's Bureau: Accordant, Biogen, Bristol Myers Squibb, Celgene, Genzyme/Sanofi, GlaxoSmithKline, Horizon Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson, Mylan, Novartis, Viela Bio.

Faculty

Joseph R. Berger, M.D
Professor of Neurology,
Associate Chief of MS Division
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
 

Disclosures: Grant/Research Support: Biogen and Genentech/Roche. Consultant: Celgene/Bristol Myers Squibb, Cellevolve, EMD Serono/Merck & Co, Genentech/Roche, Genzyme, Janssen/Johnson & Johnson, Morphic Therapeutic, NeuVIR, Novartis, Sanofi, Takeda, and TG Therapeutics. Other Support: Scientific Advisory or Data Safety Monitoring board for MAPI and Excision Bio Therapeutics.
 

Clyde E. Markowitz, MD
Director, Multiple Sclerosis Center
Associate Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
 

Disclosures: Consultant: Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb, Celgene, Genentech/Roche, Genzyme/Sanofi, Merck & Co/EMD Serono, Novartis, Teva Pharmaceuticals.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.